Reports sees evolution in pharmaceuticals

An ARC Advisory Group product story
Edited by the Engineeringtalk editorial team Apr 6, 2006

Report says because of limited capital, equipment and talented human assets, increasing asset use and return on assets is vital to future success and survival for pharmaceutical manufacturing.

Pharmaceutical manufacturing is evolving from a high margin, large volume, make-to-stock, supply-driven operation to a price sensitive, small volume, flexible, make-to-order, personalised, value-driven services operation, according to a report.

With limited available capital, equipment and talented human assets, increasing asset use and return on assets is becoming vital to future success and survival.

Companies are building manufacturing cultures that foster innovation and teamwork while using common tools, technologies and standards that deliver added value and financial benefit to their businesses.

"The pharmaceutical industry is in rapid transition from a supply-driven market to a demand- and service-driven market where manufacturing efficiency and responsiveness will play a critical role in future success", said Asish Ghosh, author of ARC's Pharmaceutical Industry Automation Worldwide Outlook.

Leading suppliers are keenly aware of the quickening pace of IT adoption in the building automation systems (BAS) market and are working hard to expand strategic differentiators to improve competitive advantage over peers.

ARC expects BAS to expand in functionality to fit a broader range of applications from the largest enterprises to more focused methods that can grow in functionality as companies increase investments.

Regulatory requirements in the life sciences and food markets are fuelling significant investments in integrated BAS products.

Companies in the life sciences industries are realising the importance of integrated BAS to meet the requirements of 21 CFR Part 11, the electronic-recordkeeping requirements imposed by the Food and Drug Association in the USA.

Integrated BAS products significantly reduce the cost and time to achieving and maintaining regulatory compliance for manufacturers in the life sciences market.

Key areas of cost savings include reduced project engineering, training, documentation and maintenance costs.

Current manufacturing, regulatory and technology deployment activities are placing additional emphasis on patient safety.

However, the growth of counterfeit and grey market drugs, the recent exposure of a limited drug manufacturing and delivery system capacity, increased regulatory and customer requirements, and an increased number of litigations continue to require deployment of additional technology that is affecting production, business operations and supply chain processes.

These deployments include product authentication, tracking and tracing with barcode and RFID technologies, anti-counterfeit measures in packaging, and product formulation.

Not what you're looking for? Search the site.

Back to top Back to top

Google Ads

 

Contact ARC Advisory Group

Related Stories

Contact ARC Advisory Group

 

Newsletter sign up

Request your free weekly copy of the Engineeringtalk email newsletter ...

Articles by product category

All suppliers A - Z

A Pro-talk Publication

A Pro-talk publication